Trials / Completed
CompletedNCT00314132
Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.
Randomised, Double Blind, Multicentre, Placebo Controlled Phase III Study of the Safety and Tolerability Following Administration of Live Attenuated JE Vaccine (ChimeriVax™-JE)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,004 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess whether ChimeriVax™ JE vaccine (a new vaccine to be used for vaccination against Japanese encephalitis) is safe and well tolerated when compared to placebo (dummy) vaccination.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ChimeriVax-JE, Japanese Encephalitis vaccine | 0.5 mL, Subcutaneous |
| BIOLOGICAL | 0.9% Saline | 0.5 mL, Subcutaneous |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2006-11-01
- Completion
- 2006-11-01
- First posted
- 2006-04-13
- Last updated
- 2012-12-06
- Results posted
- 2012-12-05
Locations
22 sites across 2 countries: United States, Australia
Source: ClinicalTrials.gov record NCT00314132. Inclusion in this directory is not an endorsement.